When Reshu Basnyat first found a lump in her breast in February 2023, she wasn't too alarmed. The Melbourne finance worker, 33, assumed it was hormonal - a temporary change after a pregnancy loss ...

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

The FDA granted traditional approval to pirtobrutinib (Jaypirca) for relapsed/refractory chronic lymphocytic leukemia/small ...

Abemaciclib is the first CDK4/6 inhibitor to produce a significant overall survival benefit in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer, ...

Three abstracts will be presented during the annual San Antonio Breast Cancer Symposium (SABCS) taking place December 9-12, 2025, in San Antonio, TX. These presentations underscore the growing ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing novel therapies in oncology, including (Z)-endoxifen, to improve outcomes for patients across the ...

The Office star Jenna Fischer revealed her battle with stage 1 triple-positive breast cancer, diagnosed in late 2023 after a ...

Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will present a wide range of new breast cancer research at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting ...

Despite recent progress in understanding the disease, inflammatory breast cancer (IBC) remains a challenge to diagnose and ...